Table 2 Baseline characteristics of the patient cohort

Demographic characteristics

 Age, years

  Mean (SD)

45 (26)

56 (17)

6 (5)

  Median (IQR)

51 (24,66)

58 (43,69)

4 (1,9)

 Sex, n (%)

  Females, n (%)

4,053 (51.4%)

3,242 (52.7%)

811 (46.6%)

 Residence, n (%)

  Urban

6,697 (84.9%)

5,187 (84.4%)

1,510 (86.7%)

  Northern Alberta

3,960 (50.2%)

3,295 (53.6%)

665 (38.2%)

  Southern Alberta

3,930 (49.8%)

2,853 (46.4%)

1,077 (61.8%)

Clinical characteristics

 Charlson Comorbidity Index

  Score, mean (SD)

1.6 (2.2)

1.8 (2.3)

0.7 (1.7)

 Comorbidities within the index, n (%)

  Cancer

1,307 (16.6%)

1,145 (18.6%)

162 (9.3%)

  Chronic pulmonary disease

1,208 (15.3%)

1,106 (18.0%)

102 (5.9%)

  Diabetes

1,169 (14.8%)

1,140 (18.5%)

29 (1.7%)

  Rheumatoid disease

694 (8.8%)

647 (10.5%)

47 (2.7%)

  Renal disease

606 (7.7%)

557 (9.1%)

49 (2.8%)

  Heart failure

514 (6.5%)

480 (7.8%)

34 (2.0%)

  Liver disease

392 (5.0%)

335 (5.5%)

57 (3.2%)

  Cerebrovascular disease

378 (4.8%)

335 (5.5%)

43 (2.5%)

  Myocardial infarction

252 (3.2%)

 > 243 (> 4.0%)

 < 10

  Metastatic cancer

252 (3.2%)

200 (3.3%)

52 (3.0%)

  Peripheral vascular disease

210 (2.7%)

184 (3.0%)

26 (1.5%)

  Hemiplegia or paraplegia

168 (2.1%)

110 (1.8%)

58 (3.3%)

  Peptic ulcer

148 (1.9%)

 > 139 (> 2.3%)

 < 10

  Dementia

76 (1.0%)

76 (1.2%)

N/A

 Primary or secondary immunodeficiency, n (%)

1,872 (23.7%)

1,692 (27.5%)

180 (10.3%)

 IgG administration on the index date, n (%)

  IVIg

7,547 (95.7%)

5,819 (94.7%)

1,728 (99.2%)

  SCIg

343 (4.3%)

329 (5.3%)

14 (0.8%)

   Self-administered

 > 334 (> 4.2%)

 > 320 (> 5.2%)

 > 10 (> 0.6%)

   Clinic-administered

 < 10

 < 10

 < 10